To view video, and read the full article visit URL http://crweselect.com/28469/stock-alerts/thld-sya-sti-shbi-crweselectcom…
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
Threshold Pharmaceuticals, Inc. – Symbol THLD – announced that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug.
TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions, a hallmark for many cancer indications. Areas of low oxygen levels (hypoxia) within tissues are common in many solid tumors due to insufficient blood vessel growth. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be extremely hypoxic.
TH-302 has been investigated in over 550 patients in Phase I/II clinical trials to date in a broad spectrum of tumor types, both as a monotherapy and in combination with chemotherapy treatments and other targeted cancer drugs.
Threshold has several ongoing clinical trials including, but not limited to, a controlled Phase 2 trial of TH-302 in combination with gemcitabine versus gemcitabine alone in patients with advanced pancreatic cancer and a Phase 3 study evaluating TH-302 in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma.
Threshold Pharmaceuticals will receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012.
Threshold Pharmaceuticals is also eligible to receive a $20 million milestone payment based on positive results from its randomized Phase 2 trial in pancreatic cancer. Total potential milestone payments are $525 million, comprised of $280 million in regulatory and development milestones and $245 million in sales-based milestones.
THLD is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of patients with some hematologic malignancies.
For more information about THLD please visit http://www.thresholdpharm.com
****
Symetra Financial Corporation (NYSE: SYA) recently reported fourth quarter 2011 net income of $74.2 million, or $0.54 per diluted share. This compares with $62.2 million, or $0.45 per diluted share, in fourth quarter 2010. For full-year 2011, Symetra produced net income of $199.6 million, or $1.45 per diluted share, compared with $200.9 million, or $1.48 per diluted share, in 2010. Adjusted operating income1 was $51.6 million, or $0.38 per diluted share, in fourth quarter 2011, compared with $48.0 million, or $0.35 per diluted share, in fourth quarter 2010. For full-year 2011, Symetra generated adjusted operating income of $194.1 million, or $1.41 per diluted share, compared with $175.2 million, or $1.29 per diluted share, in 2010.
Symetra Financial Corporation, through its subsidiaries, provides group and individual insurance products and retirement products in the United States and the District of Columbia.
****
SunTrust Banks, Inc. (NYSE: STI) is scheduled to make a presentation at the Credit Suisse Financial Services Forum in Miami, Florida on Friday, February 10, 2012. 11:45 a.m. (ET) Presenter: Aleem Gillani, Chief Financial Officer of SunTrust Banks, Inc.
SunTrust Banks, Inc. operates as the holding company for SunTrust Bank, which provides various financial services to consumer and corporate customers in the United States.
****
Shore Bancshares, Inc. (NASDAQ: SHBI) previously reported net income of $325 thousand, or $0.04 per diluted common share, for the fourth quarter of 2011, compared to net income of $94 thousand, or $0.01 per diluted common share, for the third quarter of 2011 and net income of $850 thousand, or $0.10 per diluted common share, for the fourth quarter of 2010. The Company reported a net loss of $897 thousand, or $(0.11) per diluted common share, for 2011, compared to a net loss of $1.7 million, or $(0.20) per diluted common share, for 2010.
Shore Bancshares, Inc. operates as the holding company for The Centreville National Bank of Maryland; The Talbot Bank of Easton, Maryland; and The Felton Bank, which provide various commercial and consumer banking products and services in Maryland and Delaware.
To read the full article visit URL http://crweselect.com/28469/stock-alerts/thld-sya-sti-shbi-crweselectcom…
*****************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
THLDcrweselect0204
